KeyBank National Association
ESPR

KeyBank National Association’s Esperion Therapeutics ESPR Stock Holding History

KeyBank National Association’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-5,903
Closed -$262K – 965
2018
Q3 		$262K Sell
5,903
-1,760
-23% -$80.8K ﹤0.01% 935
2018
Q2 		$300K Buy
7,663
+3,787
+98% +$191K ﹤0.01% 876
2018
Q1 		$280K Sell
3,876
-1,115
-22% -$81.9K ﹤0.01% 894
2017
Q4 		$329K Hold
4,991
– – ﹤0.01% 864
2017
Q3 		$250K Sell
4,991
-1,863
-27% -$89.8K ﹤0.01% 967
2017
Q2 		$317K Sell
6,854
-334
-5% -$12.3K ﹤0.01% 935
2017
Q1 		$254K Sell
7,188
-5,503
-43% -$126K ﹤0.01% 1015
2016
Q4 		$159K Buy
+12,691
New +$151K ﹤0.01% 1099
2016
Q2 		– Sell
-10,599
Closed -$179K – 1107
2016
Q1 		$179K Buy
+10,599
New +$170K ﹤0.01% 1046
2015
Q3 		– Sell
-3,691
Closed -$302K – 1160
2015
Q2 		$302K Buy
3,691
+415
+13% +$40.6K ﹤0.01% 1003
2015
Q1 		$303K Buy
+3,276
New +$211K ﹤0.01% 1012
2014
Q1 		– Sell
-10,693
Closed -$147K – 1271
2013
Q4 		$147K Buy
+10,693
New +$156K ﹤0.01% 1230

Other funds holding ESPR

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KeyBank National Association's ESPR Position: Q4 2018 in Review

KeyBank National Association sold out of Esperion Therapeutics (ESPR) in Q4 2018, closing a stake of 5,903 shares — an estimated $262K sold.

KeyBank National Association first reported a position in ESPR in Q4 2013 and held it in 12 quarters. The position peaked at $329K in Q4 2017. 156 funds tracked by Wall St. Rank hold ESPR as of Q4 2018.

  • KeyBank National Association reported no remaining Esperion Therapeutics position as of Q4 2018 after selling out during the quarter.
  • KeyBank National Association sold 5,903 Esperion Therapeutics shares in Q4 2018, an estimated $262K.
  • KeyBank National Association first reported a position in Esperion Therapeutics in Q4 2013 and held it in 12 quarters.
  • KeyBank National Association's Esperion Therapeutics position peaked at $329K in Q4 2017.
  • 156 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2018.

Based on KeyBank National Association's 13F filing for Q4 2018, filed 30 Jan 2019.